A PYMNTS Company

EU: First drug maker appeals pay-for-delay penalty

By  |  July 11, 2014

At least one drug maker sanctioned earlier this month by the European Commission for pay-for-delay agreements has appealed the sanction, according to reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Pharmaceutical firm Mylan, which owns Matrix laboratories – one of the companies fined by the Commission – will challenge the fines that were imposed after the Commission found Matrix to have struck anticompetitive agreements with France’s Servier Laboratories to delay Matrix’s generic, cheaper form of a competing drug.

    Five companies in total were fined by the Commission. Lupin and Unichem, also fined, also vowed to appeal the ruling.

    Full content: Hindu Business Line

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.